Shannon L Maude Selected Research

tisagenlecleucel

1/2022	Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.
1/2022	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
1/2022	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19.
1/2022	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy.
12/2021	Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.
10/2021	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
10/2021	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.
1/2021	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
10/2020	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.
11/2019	CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shannon L Maude Research Topics

Disease

34	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 08/2012
17	Cytokine Release Syndrome 01/2022 - 06/2013
15	Neoplasms (Cancer) 01/2022 - 02/2005
8	Leukemia 01/2022 - 10/2012
3	Sepsis (Septicemia) 01/2022 - 02/2014
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2016
3	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 06/2013
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 11/2017
3	Critical Illness (Critically Ill) 10/2020 - 01/2016
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 01/2018
2	Residual Neoplasm 01/2022 - 12/2020
2	Fever (Fevers) 10/2021 - 02/2017
2	Infections 01/2021 - 01/2020
2	Bites and Stings (Sting) 01/2018 - 06/2013
2	Hyperferritinemia 02/2017 - 06/2013
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022
1	Down Syndrome (Down's Syndrome) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Central Nervous System Diseases (CNS Diseases) 10/2021
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2020
1	Glucocorticoid Receptor Deficiency 01/2019
1	Philadelphia Chromosome 01/2019
1	Multiple Myeloma 01/2018
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2017
1	Respiratory Insufficiency (Respiratory Failure) 02/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017
1	Body Weight (Weight, Body) 10/2014
1	Macrophage Activation Syndrome 03/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2014
1	Cytopenia 06/2013
1	Genomic Instability 04/2006
1	Carcinogenesis 04/2006

Drug/Important Bio-Agent (IBA)

29	Chimeric Antigen ReceptorsIBA 01/2022 - 10/2014
18	tisagenlecleucelIBA 01/2022 - 10/2014
5	tocilizumab (atlizumab)FDA Link 01/2022 - 10/2014
5	CytokinesIBA 10/2020 - 06/2013
4	AntibodiesIBA 01/2022 - 06/2013
3	blinatumomabIBA 01/2022 - 06/2013
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2014
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
3	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2018
2	siltuximabIBA 01/2022 - 01/2016
2	CD19-specific chimeric antigen receptorIBA 01/2020 - 01/2016
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2019 - 08/2012
2	Phosphotransferases (Kinase)IBA 01/2019 - 08/2012
2	CD19 AntigensIBA 12/2015 - 12/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2006 - 02/2005
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	Inotuzumab OzogamicinIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	ProteomeIBA 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	EmapalumabIBA 01/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2022
1	Biological ProductsIBA 10/2020
1	Death Domain ReceptorsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	AntigensIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2018
1	daratumumabIBA 01/2018
1	Ferritins (Ferritin)IBA 02/2017
1	Surface Antigens (Surface Antigen)IBA 01/2017
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2016
1	EpitopesIBA 12/2015
1	InterferonsIBA 03/2014
1	InterleukinsIBA 03/2014
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 06/2013
1	Sirolimus (Rapamycin)FDA Link 10/2012
1	ruxolitinibIBA 10/2012

Therapy/Procedure

26	Therapeutics 01/2022 - 04/2006
11	Immunotherapy 01/2022 - 01/2016
6	Drug Therapy (Chemotherapy) 01/2022 - 02/2005
2	Critical Care (Surgical Intensive Care) 02/2017 - 02/2014
1	Castration 01/2022
1	Retreatment 01/2021
1	Artificial Respiration (Mechanical Ventilation) 02/2017